Dataset Information


Inhibition of polycomb repressive complex 2 by targeting EED protects against cisplatin-induced acute kidney injury.

ABSTRACT: Polycomb repressive complex 2 (PRC2) is a multicomponent complex with methyltransferase activity that catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3). Interaction of the epigenetic reader protein EED with EZH2, a catalytic unit of PRC, allosterically stimulates PRC2 activity. In this study, we investigated the role and underlying mechanism of the PRC2 in acute kidney injury (AKI) by using EED226, a highly selective PRC2 inhibitor, to target EED. Administration of EED226 improved renal function, attenuated renal pathological changes, and reduced renal tubular cell apoptosis in a murine model of cisplatin-induced AKI. In cultured renal epithelial cells, treatment with either EED226 or EED siRNA also ameliorated cisplatin-induced apoptosis. Mechanistically, EED226 treatment inhibited cisplatin-induced phosphorylation of p53 and FOXO3a, two transcriptional factors contributing to apoptosis, and preserved expression of Sirtuin 3 and PGC1α, two proteins associated with mitochondrial protection in vivo and in vitro. EED226 was also effective in enhancing renal tubular cell proliferation, suppressing expression of multiple inflammatory cytokines, and reducing infiltration of macrophages to the injured kidney. These data suggest that inhibition of the PRC2 activity by targeting EED can protect against cisplatin-induced AKI by promoting the survival and proliferation of renal tubular cells and inhibiting inflammatory response.

PROVIDER: S-EPMC9279598 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC5224880 | BioStudies
| S-EPMC7004250 | BioStudies
| S-EPMC8389561 | BioStudies
| S-EPMC2857112 | BioStudies
| S-EPMC5708817 | BioStudies
| S-EPMC7642668 | BioStudies
| S-EPMC8512008 | BioStudies
| S-EPMC5833747 | BioStudies
| S-EPMC6970081 | BioStudies
2019-01-01 | S-EPMC6714212 | BioStudies